Background Outcomes of ketamine intravenous therapy (KIT) for depression in real-world
care settings have been minimally evaluated. We set out to quantify treatment response to …

Introduction Ketamine intravenous therapy (KIT) appears effective for treating depression in
controlled trials testing a short series of infusions. A rapidly proliferating number of clinics …

Background Little is known about the long-term outcomes of repeated ketamine infusions for
depression. We conducted a retrospective chart review to investigate outcomes of …

Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset
antidepressant properties, but little is known regarding which patients are most likely to …

Background Recent studies demonstrating a rapid, robust improvement in treatment
resistant depression (TRD) following a single sub-anesthetic infusion of ketamine have …

Objective: Subanesthetic ketamine doses have been shown to have rapid yet transient
antidepressant effects in patients with treatment-resistant depression, which may be …

Background Ketamine is known to rapidly reduce depressive symptoms and suicidal
ideation (SI) in patients with major depressive disorder (MDD), but evidence is limited for its …

Background Sub-anaesthetic administration of ketamine is an emerging practice in patients
presenting treatment resistant depression (TRD), however several outstanding questions …

Background Ketamine has been documented for its rapid antidepressant effects. However,
optimal dose and delivery route have not yet been thoroughly investigated. The objectives of …

Objective We conducted an open-label clinical trial (“Bio-K”) using IV ketamine for treatment-
resistant depression to identify biomarkers linked to remission. Here, we report the clinical …